OMEROS CORP Total Liabilities and Equity
OMEROS CORP (OMER) had Total Liabilities and Equity of $286.83 million as of 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Balance Sheet
us-gaap:LiabilitiesAndStockholdersEquity · last filed 2026-08-12
- 2026-06-30: Liabilities and Equity $286.83M.
- 2026-03-31: Liabilities and Equity $286.17M.
- 2025-12-31: Liabilities and Equity $325.63M.
- 2025-09-30: Liabilities and Equity $185.71M.
| Period end | Liabilities and Equity | Liabilities and Equity as first filed |
|---|---|---|
| 2026-06-30 | $286.83M 10-Q · filed 2026-08-12 | |
| 2026-03-31 | $286.17M 10-Q · filed 2026-05-13 | |
| 2025-12-31 | $325.63M 10-Q · filed 2026-08-12 | |
| 2025-09-30 | $185.71M 10-Q · filed 2025-11-13 | |
| 2025-06-30 | $200.57M 10-Q · filed 2025-08-14 | |
| 2025-03-31 | $235.16M 10-Q · filed 2025-05-15 | |
| 2024-12-31 | $277.08M 10-K · filed 2026-03-31 | |
| 2024-09-30 | $313.33M 10-Q · filed 2024-11-13 | |
| 2024-06-30 | $356.31M 10-Q · filed 2024-08-07 | |
| 2024-03-31 | $437.49M 10-Q · filed 2024-05-15 | |
| 2023-12-31 | $378.27M 10-K · filed 2025-03-31 | |
| 2023-09-30 | $493.07M 10-Q · filed 2023-11-09 | |
| 2023-06-30 | $527.42M 10-Q · filed 2023-08-09 | |
| 2023-03-31 | $560.13M 10-Q · filed 2023-05-09 | |
| 2022-12-31 | $590.97M 10-K · filed 2024-04-01 | |
| 2022-09-30 | $457.55M 10-Q · filed 2022-11-09 | |
| 2022-06-30 | $345.64M 10-Q · filed 2022-08-09 | |
| 2022-03-31 | $369.26M 10-Q · filed 2022-05-10 | |
| 2021-12-31 | $419.27M 10-K · filed 2023-03-13 | |
| 2021-09-30 | $123.43M 10-Q · filed 2021-11-09 | |
| 2021-06-30 | $145.39M 10-Q · filed 2021-08-09 | |
| 2021-03-31 | $161.44M 10-Q · filed 2021-05-10 | |
| 2020-12-31 | $181.04M 10-K · filed 2022-03-01 | |
| 2020-09-30 | $227.07M 10-Q · filed 2020-11-09 | |
| 2020-06-30 | $70.69M 10-Q · filed 2020-08-10 | |
| 2020-03-31 | $118.21M 10-Q · filed 2020-05-11 | |
| 2019-12-31 | $136.97M 10-K · filed 2021-03-01 | |
| 2019-09-30 | $91.26M 10-Q · filed 2019-11-12 | |
| 2019-06-30 | $89.76M 10-Q · filed 2019-08-08 | |
| 2019-03-31 | $101.25M 10-Q · filed 2019-05-09 | |
| 2018-12-31 | $95.94M 10-K · filed 2020-03-02 | |
| 2018-09-30 | $75.61M 10-Q · filed 2018-11-08 | |
| 2018-06-30 | $106.35M 10-Q · filed 2018-08-09 | |
| 2018-03-31 | $89.03M 10-Q · filed 2018-05-10 | |
| 2017-12-31 | $116.33M 10-K · filed 2019-03-01 | |
| 2017-09-30 | $125.52M 10-Q · filed 2017-11-09 | |
| 2017-06-30 | $60.35M 10-Q · filed 2017-08-08 | |
| 2017-03-31 | $58.40M 10-Q · filed 2017-05-10 | |
| 2016-12-31 | $67.28M 10-K · filed 2018-03-01 | |
| 2016-09-30 | $72.76M 10-Q · filed 2016-11-09 | |
| 2016-06-30 | $46.11M 10-Q · filed 2016-08-09 | |
| 2016-03-31 | $35.97M 10-Q · filed 2016-05-10 | |
| 2015-12-31 | $48.99M 10-K · filed 2017-03-16 | |
| 2015-09-30 | $41.42M 10-Q · filed 2015-11-09 | |
| 2015-06-30 | $58.64M 10-Q · filed 2015-08-10 | |
| 2015-03-31 | $74.91M 10-Q · filed 2015-05-11 | |
| 2014-12-31 | $10.83M 10-K · filed 2016-03-15 | $11.09M 10-K · filed 2015-03-16 |
| 2014-09-30 | $25.29M 10-Q · filed 2014-11-10 | |
| 2014-06-30 | $40.99M 10-Q · filed 2014-08-11 | |
| 2014-03-31 | $56.07M 10-Q · filed 2014-05-12 | |
| 2013-12-31 | $16.54M 10-K · filed 2015-03-16 | |
| 2013-09-30 | $12.01M 10-Q · filed 2013-11-07 | |
| 2013-06-30 | $23.06M 10-Q · filed 2013-08-09 | |
| 2013-03-31 | $17.69M 10-Q · filed 2013-05-09 | |
| 2012-12-31 | $26.57M 10-K · filed 2014-03-13 | |
| 2012-09-30 | $32.76M 10-Q · filed 2012-11-09 | |
| 2012-06-30 | $10.07M 10-Q · filed 2012-08-07 | |
| 2012-03-31 | $21.09M 10-Q · filed 2012-05-10 | |
| 2011-12-31 | $26.98M 10-K · filed 2013-03-18 | |
| 2011-09-30 | $34.98M 10-Q · filed 2011-11-08 | |
| 2011-06-30 | $40.95M 10-Q · filed 2011-08-09 | |
| 2010-12-31 | $45.70M 10-K · filed 2012-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |